𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study

✍ Scribed by M. Benchalal; J.M. Bachaud; P. François; C. Alzieu; P. Giraud; J.M. David; N. Daly-Schveitzer

Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
275 KB
Volume
20
Category
Article
ISSN
0958-3947

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved results with accelerated hyperf
Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer
✍ Felix Leborgne; Eduardo Zubizarreta; Jack Fowler; Bettys Ortega; Julieta Mezzera 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 309 KB 👁 2 views

A retrospective study on local tumor control, survival, and complications of conventional irradiation vs. accelerated hyperfractionated irradiation in patients with selected head and neck cancer sites was undertaken. A total of 1,007 consecutive patients treated with radiation alone for cure from 19

Toxicity and survival outcomes of hyperf
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers
✍ John M. Watkins; Keisuke S. Shirai; Amy E. Wahlquist; Robert K. Stuart; Uzair B. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## __Background__. Reirradiation of locoregionally recurrent, previously irradiated head/neck cancer may be considered in situations of unresectability, medical inoperability, or adverse pathologic features found at salvage resection. ## __Methods__. Retrospective cohort analysis of

Results of a pilot study of the effects
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract
✍ Victor Lai; Jonathan George; Luther Richey; Hong J. Kim; Trinitia Cannon; Carol 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

## Abstract ## Background. Animal models suggest that cyclooxygenase‐2 (COX‐2) inhibitors may be beneficial in suppressing cancer cachexia. We investigated the effect of short‐course celecoxib on body composition, inflammation, and quality of life (QOL) in patients with cancer cachexia in a phase